Proteocyte AI Announces Partnership With Proscia Digital

Proteocyte AI announced they have signed a partnership agreement to integrate Proscia’s technology with Straticyte™, a specific test for predicting the risk of progression to oral cancer. Proteocyte AI will leverage Proscia’s cloud-based platform to orchestrate workflows of patients, doctors, and laboratories, enabling Proteocyte AI to offer a more comprehensive solution.

Click here to read the full release

Previous
Previous

OBIO Launches 'Use It or Lose It', Latest Report on the Future of Canada’s Health Science Industry

Next
Next

OBIO CAAP Company Swift Medical Raises $11.6 Million in Oversubscribed Series A